Winners / 2025

VORANIGO® (vorasidenib tablets)

By: Servier Pharmaceuticals
Silver

Master Category:

Award Category: Health, Medical & Biotech

Award Sub-Category: Advancements in Neurological Treatments

Voranigo is a first-in-class, FDA-approved medicine used to treat adults and children 12 years & older with Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation. Voranigo offers patients the ability to actively manage their disease with a once-daily pill.

Explore more Health & Wellness

Put your innovation in the spotlight.

For four decades, the Edison Awards have recognized innovative products, services, and technologies that create meaningful value and impact. Explore the categories, find the right fit, and enter your new innovation for recognition.

Ready for Nomination Season?

Complete the form below to download the 2027 Nomination Guide.

A Founders Guide to Modern Innovation
The Future of the Grid – Panel Discussion 2024 Edison Awards
Edison Award-Winning Brain Technology Featured in U.S. News & World Report